{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
bedaquiline
to a specific field?
There is one exact (name or code) match for bedaquiline
Status:
US Approved Rx
(2012)
Source:
NDA204384
(2012)
Source URL:
First approved in 2012
Source:
NDA204384
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica. When it was approved by the FDA on the 28th December 2012, it was the first new medicine to fight TB in more than forty years, and is specifically approved to treat multi-drug-resistant tuberculosis. Bedaquiline is a diarylquinoline antimycobacterial drug that inhibits the proton pump of mycobacterial ATP (adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis. Bacterial death occurs as a result of bedaquiline.
Showing 1 - 10 of 10 results
Status:
US Approved Rx
(2012)
Source:
NDA204384
(2012)
Source URL:
First approved in 2012
Source:
NDA204384
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica. When it was approved by the FDA on the 28th December 2012, it was the first new medicine to fight TB in more than forty years, and is specifically approved to treat multi-drug-resistant tuberculosis. Bedaquiline is a diarylquinoline antimycobacterial drug that inhibits the proton pump of mycobacterial ATP (adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis. Bacterial death occurs as a result of bedaquiline.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Investigational
Source:
NCT00397943: Phase 2 Interventional Completed Tuberculosis
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2012)
Source:
NDA204384
(2012)
Source URL:
First approved in 2012
Source:
NDA204384
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica. When it was approved by the FDA on the 28th December 2012, it was the first new medicine to fight TB in more than forty years, and is specifically approved to treat multi-drug-resistant tuberculosis. Bedaquiline is a diarylquinoline antimycobacterial drug that inhibits the proton pump of mycobacterial ATP (adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis. Bacterial death occurs as a result of bedaquiline.
Status:
Possibly Marketed Outside US
Source:
NCT00442962: Phase 4 Interventional Completed HIV Infections
(2007)
Source URL:
First approved in 1946
Source:
NDA006035
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Maleic acid monosodium salt. Used in water soluble polymers preparation.
